Back to top
more

Salarius Pharmaceuticals (SLRX)

(Delayed Data from NSDQ)

$0.46 USD

0.46
20,620

0.00 (0.37%)

Updated May 31, 2024 04:00 PM ET

After-Market: $0.47 +0.01 (1.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SLRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Salarius Pharmaceuticals, Inc. [SLRX]

Reports for Purchase

Showing records 21 - 40 ( 44 total )

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

03/11/2022

Company Report

Pages: 5

Salarius? 4Q21 Results; Programs On Course With Many Catalysts in 2022; Reiterate Buy and Reduce PT to $4 from $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

01/14/2022

Company Report

Pages: 5

Notable Acquisition Expands Pipeline into Large Targeted Protein Degradation Market

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

01/13/2022

Daily Note

Pages: 4

Salarius Enters Protein Degradation After Buying Portfolio of "Molecular Glues"

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

12/29/2021

Daily Note

Pages: 3

New Seclidemstat Dosing Milestone for Phase 1/2 Sarcoma Trial; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

11/08/2021

Company Report

Pages: 6

New Collaborations with Top Institutions Expands Research

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/05/2021

Company Report

Pages: 5

Salarius Secures Solid 3Q21 Financials and Ramps Up Seclidemstat Development; Reiterate Buy and Maintain PT of $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

10/08/2021

Daily Note

Pages: 6

Seclidemstat''s Anti-Tumor Mechanisms in FET Rearranged Sarcomas Uncovered in New Study; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SLRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

09/22/2021

Daily Note

Pages: 3

Salarius-Fox Chase Cancer Center to Uncover Novel Indications and Biomarkers for Seclidemstat; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

08/25/2021

Company Report

Pages: 83

We initiate coverage with a Buy rating and a 12-month price target of $5.

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 150.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

08/09/2021

Company Report

Pages: 6

Maximizing Potential of Seclidemstat as Cancer Treatment, Supported by Strong Balance Sheet

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

06/28/2021

Company Report

Pages: 5

Highlights From Key Opinion Leader (KOL) Event

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

05/26/2021

Company Report

Pages: 6

Strongest Balance Sheet in Company?s History Provides Runway to Complete Active Clinical Trials of Seclidemstat

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

03/24/2021

Company Report

Pages: 6

Strongly Positioned to Reach Inflection Points

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

02/22/2021

Company Report

Pages: 4

Important Milestone for Seclidemstat

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

11/23/2020

Company Report

Pages: 6

Lead Clinical Program Advancing, With Near Term Catalysts

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

08/19/2020

Company Report

Pages: 5

Quarterly Results as Expected, With Numerous Catalysts Over Next 12 Months

Provider: DIAMOND EQUITY RESEARCH LLC

Analyst: DIAMOND H

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

08/05/2020

Company Report

Pages: 5

Financing Facilitates Expanded Clinical Program to Develop Seclidemstat For Broader Patient Populations

Provider: DIAMOND EQUITY RESEARCH LLC

Analyst: DIAMOND H

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

05/21/2020

Company Report

Pages: 5

Numerous Upcoming Clinical Milestones with Limited COVID-19 Disruption to Date

Provider: DIAMOND EQUITY RESEARCH LLC

Analyst: DIAMOND H

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

04/15/2020

Company Report

Pages: 5

Limited disruption from COVID-19 with Dose Escalation Milestone Reached

Provider: DIAMOND EQUITY RESEARCH LLC

Analyst: DIAMOND H

Price: 10.00

Research Provided by a Third Party